Publications (302) Juan Jesús Cruz Hernández publications


  1. Biología celular y molecular del cáncer

    Oncología clínica (Arán Ediciones), pp. 13-23

  2. Diagnóstico nosológico y de extensión. Factores pronósticos

    Oncología clínica (Arán Ediciones), pp. 59-71

  3. Epidemiología del cáncer. Factores de riesgo y carcinogénesis

    Oncología clínica (Arán Ediciones), pp. 25-42

  4. Indicators to evaluate quality of care in head and neck cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097

  5. Oncología clínica coord.

    Arán Ediciones

  6. Tumores de origen desconocido

    Oncología clínica (Arán Ediciones), pp. 407-418


  1. Acute esophageal necrosis induced by immune checkpoint inhibitors

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 3, pp. 182-183

  2. Adaptation and validation of the Spanish version of the everyday cognition battery for assessing everyday cognition in older adults

    BMC Geriatrics, Vol. 22, Núm. 1

  3. Cardiac magnetic resonance to detect different patterns of myocardial injury in patients receiving immune checkpoint inhibitors

    Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 266-269

  4. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

    European Urology Focus, Vol. 8, Núm. 6, pp. 1673-1682

  5. Epidemiological Study of Prostate Cancer in the Province of Salamanca (2006-2015)

    Archivos espanoles de urologia, Vol. 75, Núm. 7, pp. 630-637

  6. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  7. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

  8. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

    Oral Oncology, Vol. 134